Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae - PubMed (original) (raw)

Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae

M J Crain et al. Infect Immun. 1990 Oct.

Abstract

Pneumococcal surface protein A (PspA) has been shown previously to elicit antibodies protective against pneumococcal infection and to be necessary for full pneumococcal virulence in mice. The protein was originally defined by the two mouse monoclonal antibodies Xi64 and Xi126, which together recognized PspA on 14% of pneumococcal isolates. Some PspA molecules reacted with both antibodies, but most reacted with only one or the other. In the present study we demonstrated that PspA is produced by all pneumococci, confirming our hypothesis that there are variants of PspA which are not detected by Xi64 and Xi126. We produced a rabbit antiserum and five additional monoclonal antibodies specific for PspA for these studies. The rabbit antiserum reacted with each of 95 pneumococcal isolated tested, comprising 16 capsular serotypes. One or more of the seven monoclonal anti-PspA antibodies reacted with 95% (53 of 57) of pneumococcal isolates tested. The specificity of the monoclonal and polyclonal antibodies to PspA was confirmed in two ways: (i) by detection of molecules on wild-type pneumococci that are identical in molecular weight to those detected in Western blots (immunoblots) with Xi64 and Xi126 and (ii) by the use of mutants of Streptococcus pneumoniae that fail to produce PspA or that produce a truncated form of PspA. By using the seven monoclonal antibodies, we observed 31 PspA types among the 57 isolates. When the 53 strains reactive with the monoclonal antibodies were analyzed by capsular type as well as by serologic type and molecular weight of PspA, we observed 50 different clonotypes of pneumococci.

PubMed Disclaimer

Similar articles

• PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.
  McDaniel LS, Sheffield JS, Delucchi P, Briles DE. McDaniel LS, et al. Infect Immun. 1991 Jan;59(1):222-8. doi: 10.1128/iai.59.1.222-228.1991. Infect Immun. 1991. PMID: 1987036 Free PMC article.
• Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae.
  Waltman WD, McDaniel LS, Gray BM, Briles DE. Waltman WD, et al. Microb Pathog. 1990 Jan;8(1):61-9. doi: 10.1016/0882-4010(90)90008-e. Microb Pathog. 1990. PMID: 2333033
• Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
  Gor DO, Ding X, Briles DE, Jacobs MR, Greenspan NS. Gor DO, et al. Infect Immun. 2005 Mar;73(3):1304-12. doi: 10.1128/IAI.73.3.1304-1312.2005. Infect Immun. 2005. PMID: 15731027 Free PMC article.
• Systemic and mucosal protective immunity to pneumococcal surface protein A.
  Briles DE, Tart RC, Wu HY, Ralph BA, Russell MW, McDaniel LS. Briles DE, et al. Ann N Y Acad Sci. 1996 Oct 25;797:118-26. doi: 10.1111/j.1749-6632.1996.tb52954.x. Ann N Y Acad Sci. 1996. PMID: 8993356 Review.
• Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).
  Briles DE, Tart RC, Swiatlo E, Dillard JP, Smith P, Benton KA, Ralph BA, Brooks-Walter A, Crain MJ, Hollingshead SK, McDaniel LS. Briles DE, et al. Clin Microbiol Rev. 1998 Oct;11(4):645-57. doi: 10.1128/CMR.11.4.645. Clin Microbiol Rev. 1998. PMID: 9767061 Free PMC article. Review.

Cited by

• Natural materno-fetal transfer of antibodies to PspA and to PsaA.
  Baril L, Briles DE, Crozier P, King JD, Hollingshead SK, Murphy TF, McCormick JB. Baril L, et al. Clin Exp Immunol. 2004 Mar;135(3):474-7. doi: 10.1111/j.1365-2249.2003.02357.x. Clin Exp Immunol. 2004. PMID: 15008981 Free PMC article.
• Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae.
  Roche H, Ren B, McDaniel LS, Håkansson A, Briles DE. Roche H, et al. Infect Immun. 2003 Aug;71(8):4498-505. doi: 10.1128/IAI.71.8.4498-4505.2003. Infect Immun. 2003. PMID: 12874329 Free PMC article.
• Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine.
  Croney CM, Nahm MH, Juhn SK, Briles DE, Crain MJ. Croney CM, et al. Clin Vaccine Immunol. 2013 Nov;20(11):1711-8. doi: 10.1128/CVI.00381-13. Epub 2013 Sep 4. Clin Vaccine Immunol. 2013. PMID: 24006139 Free PMC article.
• Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.
  Khan N, Qadri RA, Sehgal D. Khan N, et al. Clin Vaccine Immunol. 2015 Jan;22(1):99-107. doi: 10.1128/CVI.00001-14. Epub 2014 Nov 19. Clin Vaccine Immunol. 2015. PMID: 25410204 Free PMC article.

References

1. 1. Pediatrics. 1978 Nov;62(5):721-7 - PubMed
2. 1. J Clin Invest. 1986 Oct;78(4):1020-7 - PubMed
3. 1. Infect Immun. 1989 May;57(5):1457-64 - PubMed
4. 1. Microb Pathog. 1988 Sep;5(3):159-67 - PubMed
5. 1. J Exp Med. 1987 Feb 1;165(2):381-94 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • BioCyc